Novavax (NVAX): Un Nuevo Comienzo

Novavax coronavirus vaccine most promising on the market: RA Capital Management co-founder

 

https://www.msn.com/en-us/money/video/novavax-coronavirus-vaccine-most-promising-on-the-market-ra-capital-management-co-founder/vi-BB16GfKy 

NVAX

Parece que ayer no pudo con la rayuja.......a ver si a lo largo de la semana lo consigue......

 

 Moderna's Stock Jumps After Coronavirus Vaccine Shows Positive Results In Phase 1 Clinical Trial 

Moderna Inc (NASDAQ:MRNA) is getting a big boost in Tuesday's after-hours session following a positive development on the company's coronavirus vaccine. 

What Happened? Moderna's vaccine drug shows "induced anti–SARS-CoV-2 immune responses in all participants, and no trial-limiting safety concerns were identified. These findings support further development of this vaccine." 

 The 45 enrolled participants in the Phase 1 clinical trial of the mRNA-1273 SARS-CoV-2 vaccine received their first vaccination between March 16 and April 14, 2020. 

Subiendo un 18% en el fuera de horas.

Si la vacuna de novavax obtiene un nivel de anticuerpos mayor que la competencia, agarra  que nos vamos.

Ya no sube tanto, problemas con los efectos secundarios.
https://finance.yahoo.com/news/moderna-phase-1-results-show-210000747.html

- Las acciones de biotecnología con frecuencia cotizan en alrededor de seis veces las ventas. Si NanoFlu puede obtener $ 1.7 mil millones en ventas anuales, la valoración de Novavax debería elevarse a cerca de $ 10 mil millones. (+- $ 175 / título)

- Si NVX-CoV2373 finalmente obtiene la aprobación, Novavax podría tener una vacuna de mega-producción. 

- Novavax ha licenciado su adyuvante Matrix-M para su uso en una vacuna experimental contra la malaria.

https://www.fool.com/investing/2020/07/15/3-reasons-to-buy-novavax-stock-sooner-rather-than.aspx 

Que poco me gustan estos artículos de pumpeo máximo justo antes de evento binario.....

 La UE quiere invertir 2.400 millones de euros, en hasta seis empresas que están trabajando en el desarrollo de una vacuna contra el coronavirus.  Deben ser vacunas prometedoras que estén cerca o ya en curso en ensayos clínicos.
 Los ministros de salud de la UE apoyaron el plan, en una reunión de la UE con sus colegas el pasado viernes.
 La inversión se distribuirá entre un máximo de seis empresas. Las negociaciones ya están en marcha con ciertos desarrolladores de vacunas. Las compañías que solo tienen capacidad de producción en los Estados Unidos no serán consideradas.
 La Comisión Europea presentará la estrategia completa esta semana. 

Buenas a todos.
Yo estoy en este barco desde 2015 intentando entender este mundo de las pharmas, desde Nasdaqlandia, desde los misiles de Sergio, desde las carreras en pelotas de Pat por la Castellana, desde los consejos de vende ya de Framus y desde el gran batacazo...
Quiero agradecer a todos desde aquel entonces hasta ahora por vuestros consejos y sobre todo por toda la "sapiencia" que nos aportáis a diario.
Mi gran duda o no entendimiento es: Como es posible que Moderna, que no tiene ni un solo producto en el mercado cotiza ya en Nasdaq100, con una capitalización de mercado cercano a los 30 billones? Y Novavax en sus mejores tiempos de especulación no llego a los 5 billones?.
Ya no hablo de ahora, ahora Novavax ya cuenta con un producto cercano a la fase ce comercialización como el NanoFlu, y cotiza en sus máximos de Capitalización (6,5B), muy por debajo de Moderna, Es normal? Quién está detrás? Es tan real eso?
Alguien me podría responder coherentemente?
Muchas gracias a todos, y espero que nos podamos juntar y poder asistir y conoceros. Esperemos que esta vez sí podamos (por lo menos estaremos vacunados con la vacuna de Novavax, eso espero...)
Abrazo

Esa noticia (La de la estrategia de la colisión europea) no es de hace un mes?

Si pero el desenlace será próximamente. Ten en cuenta que repartir 2.400millones para la vacuna con tantos paises y burocracia de por medio no hace nada fácil la labor. No es lo misma la toma de decisiones en USA que en la UE... 

 

Oxford scientists believe they have made a breakthrough in their quest for a Covid-19 vaccine after discovering that the jab triggers a response that may offer a "double defence" against the virus.Phase I human trials of the world-leading Oxford vaccine have shown that it generates an immune response against the disease, the Telegraph has learned.Blood samples taken from a group of UK volunteers given a dose of the vaccine showed that it stimulated the body to produce both antibodies and ‘killer T-cells’, a senior source said.The discovery is promising because separate studies have suggested that antibodies may fade away within months while T-cells can stay in circulation for years.However the source cautioned that the results, while “extremely promising”, did not yet prove that the Oxford vaccine provides long-lasting immunity against Covid-19.“I can tell you that we now know the Oxford vaccine covers both bases - it produces both a T cell and an antibody response,” the senior source told the Telegraph.“It’s the combination of these two that will hopefully keep people safe.“So far, so good. It’s an important moment. But we still have a long way to go.”Show moreAnother source close to the team described the presence of both antibodies and T-cells as a “double defence” against Covid-19.The full findings will be published in the Lancet medical journal on July 20, it was confirmed on Wednesday night.The findings are based on initial results from a Phase 1 clinical trial, which began in Oxford in April when doses of the vaccine were given to 500 volunteers. A major trial is currently underway involving 5,000 volunteers in virus-hit Brazil to prove the vaccine is effective, while the drugmaker AstraZeneca has signed a deal to produce up to two billion doses. If all goes well, the researchers hope the vaccine may be ready as early as October.The initial data also suggests that the ChAdOx1 nCoV-19 vaccine is safe with no major side effects, it is understood, although further work will be needed. The team is also evaluating the level of dose needed to produce an effective response.Stocks soared on Wednesday after reports of positive news on the Oxford vaccine to be released next week. Shares in AstraZeneca, the drugmaker licensed to produce billions of doses of the Oxford vaccine, jumped 5.2 per cemt.David Carpenter, chair of the Berkshire Research Ethics Committee (REC), which approved the Oxford trial and continues to work with scientists on amendments, told the Telegraph that the team were “absolutely on track”.“They can strengthen findings by targeting people in hospitals, healthcare professionals, where the spread is (more) likely to happen.“Nobody can put final dates.. things might go wrong but the reality is that by working with a big pharma company, that vaccine could be fairly widely available around September and that is the sort of target they are working on.”The T-cell discovery is likely to be important because scientists increasingly believe that any successful vaccine will need to trigger the production of both antibodies and T cells, which directly attack human cells that have already become infected with viruses.Earlier this year a similar vaccine against MERS invented by the same Oxford team was found to elicit high levels of T-cells, but only triggered neutralising antibodies in 44 per cent of volunteers.If the Covid vaccine can be proven in further trials to elicit a similarly strong T-cell response, the team hopes it may not need to trigger high levels of antibodies to provide meaningful protection.A number of other vaccine candidates across the world have also produced T-Cell responses, but only in smaller scale studies. Others including a major project in China are thought to be unlikely to produce T-cells when tested on humans.This week the US biotech company, Moderna, published data from a phase one trial involving 45 people showing that its RNA vaccine triggered both neutralising antibodies and T cells.The findings come amid increasing gloom over the longevity of Covid-19 antibodies. Earlier this week, a Kings College study found that people who recovered from Covid-19 appeared to lose their antibodies within months.But in a study published in Nature today researchers found that T Cells from the SARS outbreak had lasted for 17 years.Duke University Scientists in Singapore found T Cells were still circulating in potent quantities from patients who were infected in 2003. It is not known for sure if the same will be true for Covid-19, and whether the T Cells will protect against re-infection, but, speaking to The Telegraph, the lead researcher described discovery as "potentially very significant for a vaccine".The researchers also found "remarkable" levels of T cells able to latch on to Covid-19 virus within people who had never been infected with the disease.They believe these may have been triggered by the common cold and other animal coronaviruses - mainly originating in bats - and that the primed cells may also offer protection against the new virus.Professor Bartoletti, who led the research in Singapore, said this may explain why so few patients in Singapore and South East Asia have had really severe infections.He said that while these T Cells will be more common in Asia, they will be present around the world. It suggests a significant proportion of all populations will have a degree of natural immunity to Covid-19.Clinical trials of the Oxford vaccine, marking phase III in the UK and involving more than 8,000 participants, are now almost complete. The focus has now moved to Brazil and South Africa, where the disease is more prevalent, and scientists hope to gather sufficient cases within around a month.